Chimerix saw the highest growth of 2.99% in patent filings in June and 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Chimerix‘s patent filings and grants. Buy the databook here.
Chimerix has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 40% grants. The United States(US), Israel(IL), and Australia(AU) patent Office are among the top ten patent offices where Chimerix is filings its patents. Among the top granted patent authorities, Chimerix has 40% of its grants in United States(US), 40% in Israel(IL) and 20% in Australia(AU).
Roche and Johnson & Johnson could be the strongest competitors for Chimerix
Patents related to rare diseases and climate change lead Chimerix's portfolio
Chimerix has the highest number of patents in rare diseases followed by, climate change and Covid-19. For rare diseases, nearly 67% of patents were filed and 57% of patents were granted in Q2 2024.
Hepatitis b related patents lead Chimerix portfolio followed by chicken pox, and herpes zoster (shingles)
Chimerix has highest number of patents in hepatitis b followed by chicken pox, herpes zoster (shingles), yellow fever, and ebolavirus infections (ebola hemorrhagic fever). For hepatitis b, nearly 7% of patents were filed and 2% of patents were granted in Q2 2024.
For comprehensive analysis of Chimerix's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.